Michael A Horton is a notable inventor based in Nr Saffron Walden, GB. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 5 patents to his name, Horton has focused on innovations that address critical health issues.

Latest Patents

One of his latest patents involves monoclonal antibodies targeting the αvβ3 integrin receptor. This receptor is known to be expressed in large amounts on the surface of osteoclasts, which are cells associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on αvβ3 and are useful in treating conditions related to excessive bone resorption and inhibiting tumor cell growth. This innovation holds promise for advancing therapeutic options in oncology and bone health.

Career Highlights

Michael A Horton is currently associated with Genentech, Inc., a leading biotechnology company. His work at Genentech has allowed him to contribute to groundbreaking research and development in the field of monoclonal antibodies. His expertise and innovative approach have positioned him as a key figure in his area of specialization.

Collaborations

Horton has collaborated with several talented individuals in his field, including Kyung Jin Kim and Sarah Catherine Bodary. These collaborations have fostered a productive environment for innovation and have led to advancements in their shared research interests.

Conclusion

Michael A Horton is a distinguished inventor whose work in monoclonal antibodies has the potential to impact medical treatments significantly. His contributions to the field exemplify the importance of innovation in addressing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com